Cephalalgia最新文献

{"title":"Migraine and the white matter microstructure controversy: Time for a methodological reset?","authors":"Roberta Messina, Catherine D Chong","doi":"10.1177/03331024251339431","DOIUrl":"https://doi.org/10.1177/03331024251339431","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251339431"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).","authors":"Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, Gabriele Sebastianelli, Federico De Santis, Michele Corrado, Marilena Marcosano, Raffaele Ornello, Licia Grazzi, Danilo Antonio Montisano, Francesco De Cesaris, Antonio Munafò, Luisa Fofi, Alberto Doretti, Gloria Vaghi, Francesca Pistoia, Delfina Ferrandi, Stefania Battistini, Simona Sacco, Simona Guerzoni, Claudia Altamura","doi":"10.1177/03331024251335927","DOIUrl":"10.1177/03331024251335927","url":null,"abstract":"<p><p>BackgroundFocusing on calcitonin gene-related peptide (CGRP) as a specific target has changed and improved migraine management. After the positive results of monoclonal antibodies directed to the CGRP pathway (anti-CGRP mAbs), randomized controlled trials also demonstrated the efficacy of gepants in migraine prevention. The present study aimed to assess the effectiveness of atogepant in preventing migraine after a 12-week treatment in clinical practice.MethodsAdult patients with a clinical indication for atogepant 60 mg daily were screened for participation in this multicentric prospective observational cohort study. At baseline (T0) and after 12 weeks (T3) since the first atogepant administration, monthly migraine days (MMDs), monthly headache days (MHDs) and monthly acute medications (MAMs) were assessed. The co-primary endpoints were the changes in MMDs from T0 to T3 and the percentage of T3 Responders (those with a reduction of MMDs ≥50%, i.e. 50% response rate (RR)). At T0 and T3, we also collected the Headache Impact Test (HIT-6), the Migraine Disability Assessment (MIDAS) questionnaire, the Migraine Treatment Optimization Questionnaire-6 (mTOQ-6), the Migraine-Specific Quality-of-Life Questionnaire (MSQ), the 12-item Allodynia Symptom Checklist (ASC-12) and the Migraine Interictal Burden Scale (MIBS-4).ResultsOne hundred and six patients (56/106 (52.8%) with chronic migraine (CM), 93/106 (87.7%) female, aged 50.6 ± 13.2 years) from 10 Italian centers completed the 12-week observation since the first atogepant tablet intake. From baseline to T3, a reduction of 6.9 MMDs (SD 9.7; <i>p</i> < 0.001) was achieved in the whole group and, specifically, of -4.9 (SD 6.6; <i>p</i> < 0.001) in episodic migraine (EM) and of -8.6 (SD 11.7; <i>p</i> < 0.001) in CM patients. Overall, 60/106 (56.6%) of patients were Responders (60.0% in the EM and 46.4% in the CM group). Non-Responders previously experienced more ineffective treatments than Responders with anti-CGRP mAbs (65.2% vs. 43.3%, respectively, <i>p</i> = 0.031) and with onabotulinumtoxinA (56.5% vs. 28.3%, <i>p</i> = 0.005), and presented more medication overuse at baseline (55.7% vs. 44.3%, p = 0.003). However, no baseline characteristics were significantly associated with the Responder status in the multiple regression analysis. For T0 to T3, MAMs, MIDAS, ASC-12 and mTOQ-6 reduced (<i>p</i> ≤ 0.001 consistently), and MSQ role-function restriction increased (<i>p</i> = 0.026), whereas HIT-6 and MIBS-4 did not change. Only seven subjects (7/106, 6.6%) dropped out of atogepant treatment: four for lack of effectiveness and three for adverse events or poor tolerability.ConclusionsThe STAR study demonstrates the effectiveness and tolerability of atogepant 60 mg at 12 weeks in a real-world setting. Previous ineffective anti-CGRP mAbs were not a relevant prognostic factor.Trial RegistrationThe study was preregistered on clinicaltrial.gov, NCT06414044.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251335927"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure\".","authors":"Britt W H van der Arend, Floor C van Welie, Jan Versijpt, Antoinette Maassen Van Den Brink, Gisela M Terwindt","doi":"10.1177/03331024251329506","DOIUrl":"https://doi.org/10.1177/03331024251329506","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251329506"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internet and social media's role in migraine education: Headache or not headache?","authors":"Faraidoon Haghdoost","doi":"10.1177/03331024251336152","DOIUrl":"https://doi.org/10.1177/03331024251336152","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251336152"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary headache treatment with work-focus in Norway: An observational study.","authors":"Oda V Lunder, Torbjørn Wisløff, Linn-Marie Wølneberg, Aina Kristin Paulsen, Linda Hagen Aasbakken, Inger Louise Hole, Ingvild Vøllo Eliassen, Kjersti Aaseth, Espen S Kristoffersen, Kjersti G Vetvik","doi":"10.1177/03331024251332572","DOIUrl":"https://doi.org/10.1177/03331024251332572","url":null,"abstract":"<p><p>BackgroundHeadache-related sick leave is increasing in Norway. In cooperation with the Norwegian Labour and Welfare Administration we established the first Norwegian multidisciplinary headache clinic for patients with current or recurrent sick leave due to headaches. The primary objective of this study was to evaluate treatment effects on headache frequency and sick leave, and secondly to identify predictors for improvement and return-to-work.MethodsA team comprising neurologists, nurses, physiotherapists, psychologists, and job specialists treated patients aged 18-67 years with headache-related sick leave. Validated questionnaires and semi-structured interviews were conducted at baseline, 3, 6, and 12 months. Mixed effects linear and logistic regression was performed with headache days and sick leave as outcomes.ResultsOne hundred and one patients completed the 12-month follow-up. The median monthly headache days decreased from 24 (Interquartile range [IQR], 15.5-30) at baseline to 10 (IQR, 4-20) at 12 months (<i>p</i> < 0.001). Headache-related sick leave declined from 53.5% to 33.7% (<i>p</i> < 0.001). Migraine diagnosis and long-term sick leave at baseline negatively predicted for return-to-work, while female sex and low baseline headache frequency predicted favorable clinical outcomes.ConclusionMultidisciplinary treatment reduced headache frequency and increased work attendance. Our findings have potential implications for healthcare policy and resource allocation.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251332572"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine.","authors":"Alicia Gonzalez-Martinez, Diana Y Wei, Nazia Karsan, Karthik Nagaraj, Helin Gosalia, Peter J Goadsby","doi":"10.1177/03331024251331554","DOIUrl":"https://doi.org/10.1177/03331024251331554","url":null,"abstract":"<p><p>BackgroundOur knowledge of the presence and type of premonitory symptoms in patients with cluster headache is limited.MethodsPremonitory symptom presence and type in a clinical cohort of cluster headache and migraine was collated retrospectively from clinical notes, alongside a cluster headache nitroglycerin triggered experimental group and an age-matched migraine nitroglycerin experimental group. Demographic data and premonitory symptoms in cluster headache and migraine patients were analysed. The primary focus was on premonitory symptom presence and phenotype in cluster headache patients, with secondary analysis exploring associated factors and comparing spontaneous and nitroglycerin-triggered symptoms in cluster headache and migraine cohorts.ResultsAmong 164 cluster headache patients, 122/164 (74%) males, aged 45.9 ± 13.8 years (mean ± SD), 66/164 (40%) had chronic cluster headache and 32/164 (20%) had also comorbid migraine. Among them, 85% exhibited premonitory symptoms for which the presence was associated with oxygen treatment. No significant differences were found in symptom frequency between cluster headache and migraine cohorts or within spontaneous and nitroglycerin-triggered symptoms.ConclusionsThis study highlights recognizable spontaneous and nitroglycerin-triggered premonitory symptoms in cluster headache and factors potentially impacting cluster headache management, which may aid in tailoring treatment strategies for both conditions through the use of treatment prediction and early intervention.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251331554"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based guidelines for the pharmacological treatment of migraine, summary version.","authors":"Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, Haidar M Al-Khazali, Anna Ambrosini, Sait Ashina, Carlo Baraldi, Alessia Bellotti, Filippo Brighina, Paolo Calabresi, Francesco Casillo, Sabina Cevoli, Shuli Cheng, Chia-Chun Chiang, Alberto Chiarugi, Rune Häckert Christensen, Min Kyung Chu, Gianluca Coppola, Ilenia Corbelli, Santiago Crema, Roberto De Icco, Marina De Tommaso, Cherubino Di Lorenzo, Vincenzo Di Stefano, Hans-Christoph Diener, Esme Ekizoglu, Adriana Fallacara, Valentina Favoni, Kimberly N Garces, Pierangelo Geppetti, Maria Teresa Goicochea, Antonio Granato, Franco Granella, Simona Guerzoni, Woo-Seok Ha, Amr Hassan, Koichi Hirata, Jan Hoffmann, Eva-Maria Hüssler, Mona Hussein, Luigi Francesco Iannone, Bronwyn Jenkins, Alejandro Labastida-Ramirez, Anna Laporta, Morris Levin, Antonino Lupica, Edoardo Mampreso, Daniele Martinelli, Teshamae S Monteith, Ilaria Orologio, Aynur Özge, Li-Ling Hope Pan, Lavindren Luke Panneerchelvam, Mario Fp Peres, Marcio Nattan Portes Souza, Patricia Pozo-Rosich, Maria Pia Prudenzano, Silvia Quattrocchi, Innocenzo Rainero, Volodymyr Romanenko, Marina Romozzi, Antonio Russo, Grazia Sances, Paola Sarchielli, Todd J Schwedt, Marcello Silvestro, Diego Belardino Swerts, Cristina Tassorelli, Alessandro Tessitore, Mansoureh Togha, Gloria Vaghi, Shuu-Jiun Wang, Messoud Ashina, Simona Sacco","doi":"10.1177/03331024251321500","DOIUrl":"https://doi.org/10.1177/03331024251321500","url":null,"abstract":"<p><p>We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251321500"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking status migrainosus: Escalation shouldn't wait for 72 hours.","authors":"Jennifer Robblee","doi":"10.1177/03331024251334137","DOIUrl":"https://doi.org/10.1177/03331024251334137","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251334137"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 'theory of everything' for migraine pathophysiology will never exist: Insights from glial cells.","authors":"Gabriele Sebastianelli","doi":"10.1177/03331024251338171","DOIUrl":"https://doi.org/10.1177/03331024251338171","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251338171"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical comparisons between post-traumatic headache and migraine: A cross-sectional study.","authors":"Haidar M Al-Khazali, Rune H Christensen, Håkan Ashina","doi":"10.1177/03331024251331605","DOIUrl":"https://doi.org/10.1177/03331024251331605","url":null,"abstract":"<p><p>ObjectiveTo compare clinical characteristics, treatment patterns, and patient-reported outcome measures (PROMs) in persons with persistent post-traumatic headache (PTH) and those with episodic or chronic migraine (with and without medication-overuse headache).MethodsThis cross-sectional study included adults with persistent PTH following mild traumatic brain injury and adults with episodic or chronic migraine. Information on headache features, treatment patterns, and PROMs were collected via semi-structured interviews and standardized questionnaires, including the HIT-6, MIDAS, HADS, ASC-12, CSI, WHODAS-2.0, NDI, and ODI.ResultsA total of 132 participants with persistent PTH and 751 with migraine were enrolled. On average, participants with persistent PTH reported 27.2 ± 9.3 monthly headache days, and 93.9% had a migraine-like phenotype. Compared with episodic migraine, the persistent PTH group had higher MIDAS scores (72.5 [IQR, 28.0-156.0] vs. 40.0 [IQR, 20.0-62.8]; <i>P</i> < 0.001), HADS-Anxiety (6.0 [IQR, 3.3-9.0] vs. 5.0 [IQR, 3.0-7.0]; <i>P</i> = 0.003), higher HADS-Depression scores (6.0 [IQR, 3.0-9.0] vs. 3.0 [IQR, 1.0-5.0]; <i>P</i> < 0.001), CSI (67.2 [SD, 15.0] vs. 57.4 [SD, 12.5]; <i>P</i> = 0.002), WHODAS-2.0 (41.0 [IQR, 15.5-68.5] vs. 22.0 [IQR, 10.0-35.0]; <i>P </i>< 0.001), and NDI (21.0 [IQR, 16.0-27.0] vs. 14.5 [IQR, 8.0-22.0]; <i>P </i>= 0.007). No marked differences were noted between the PTH group and chronic migraine groups.ConclusionsPersons with persistent PTH show similar disability and headache profiles to those with chronic migraine. These findings underscore the need for targeted management strategies, similar to those used in chronic migraine care.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 4","pages":"3331024251331605"},"PeriodicalIF":5.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}